Avastin helps cervical cancer patients

Share this article:

Avastin and chemotherapy added four months of survival among advanced cervical cancer patients. Medpage Today reported Friday that the study, published in the New England Journal of Medicine, showed median overall survival was 17 months with Avastin vs. 13.3 using only chemotherapy. Adding Avastin to platinum-based or nonplatinum therapy did not have a significant impact on results.

“Cervical cancer patients are often mothers with minor children. This is a major advance and clinical benefit to those patients," Memorial Sloan-Kettering Cancer Center's Carol Aghajaman told Medpage.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters